HUP0201626A2 - Beültethető gélkészítmények és eljárás gyártásukra - Google Patents

Beültethető gélkészítmények és eljárás gyártásukra

Info

Publication number
HUP0201626A2
HUP0201626A2 HU0201626A HUP0201626A HUP0201626A2 HU P0201626 A2 HUP0201626 A2 HU P0201626A2 HU 0201626 A HU0201626 A HU 0201626A HU P0201626 A HUP0201626 A HU P0201626A HU P0201626 A2 HUP0201626 A2 HU P0201626A2
Authority
HU
Hungary
Prior art keywords
active ingredient
initial
explosion
preparations
mixture
Prior art date
Application number
HU0201626A
Other languages
English (en)
Inventor
Kevin J. Brodbeck
Steven J. Prestrelski
Shamim J. Pushpala
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of HUP0201626A2 publication Critical patent/HUP0201626A2/hu
Publication of HUP0201626A3 publication Critical patent/HUP0201626A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A találmány olyan eljárásokra és készítményekre vonatkozik, amelyekalkalmazásával beültethető rendszerekből származó hasznos (jótékony)hatóanyag kezdeti <robbanási< hatása csökkenthető. A készítményeketúgy állítják elő, hogy egy bioerodibilis vivőanyagot és egy abbandiszpergált hatóanyagot állítanak elő úgy, hogy a hatóanyag és egycsekély vízoldhatósággal jellemzett ágens keveréknek préseltanyagtestté formálásával, ezt az anyagtestet aprítva a hatóanyag és acsekély vízoldhatósággal jellemzett ágens keverékének préseltszemcséivé alakítják, majd a préselt szemcséket a vivőanyag egészébendiszpergálják. A készítmény előnye az eddigiekkel szemben abban áll,hogy a préselés következtében a hatóanyag lassabban oldódik, és így akezdeti <robbanási< hatás (azaz a hatóanyag kezdeti, túlságosan gyorsoldódása) csökkenthető vagy elkerülhető. Ó
HU0201626A 1999-06-04 2000-05-31 Implantable gel compositions and method of manufacture HUP0201626A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13781599P 1999-06-04 1999-06-04
PCT/US2000/015383 WO2000074650A2 (en) 1999-06-04 2000-05-31 Implantable gel compositions and method of manufacture

Publications (2)

Publication Number Publication Date
HUP0201626A2 true HUP0201626A2 (hu) 2002-12-28
HUP0201626A3 HUP0201626A3 (en) 2004-05-28

Family

ID=22479154

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201626A HUP0201626A3 (en) 1999-06-04 2000-05-31 Implantable gel compositions and method of manufacture

Country Status (18)

Country Link
US (1) US20060233841A1 (hu)
EP (1) EP1183010A2 (hu)
JP (1) JP2003501375A (hu)
KR (1) KR100844295B1 (hu)
CN (1) CN100370967C (hu)
AU (1) AU779277B2 (hu)
CA (1) CA2372994C (hu)
CZ (1) CZ20014338A3 (hu)
HK (1) HK1060856A1 (hu)
HU (1) HUP0201626A3 (hu)
IL (1) IL146814A0 (hu)
MX (1) MXPA01012471A (hu)
NO (1) NO20015888L (hu)
NZ (2) NZ530701A (hu)
PL (1) PL351948A1 (hu)
RU (1) RU2271196C2 (hu)
WO (1) WO2000074650A2 (hu)
ZA (1) ZA200109970B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011850B2 (en) 1999-12-16 2006-03-14 Alza Corporation Dosage forms having a barrier layer to laser ablation

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159624A0 (en) 2001-06-29 2004-06-01 Medgraft Microtech Inc Biodegradable injectable implants and related methods of manufacture and use
CA2466642C (en) * 2001-11-14 2011-01-18 Guohua Chen Injectable depot composition
CN1703197A (zh) * 2001-11-14 2005-11-30 阿尔扎有限公司 可注射的长效组合物和其使用
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
CA2474698C (en) * 2002-02-08 2009-07-21 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7432245B2 (en) 2002-06-07 2008-10-07 Abbott Laboratories Inc. Pharmaceutical formulation comprising a peptide angiogenesis inhibitor
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
ES2319400T3 (es) 2002-07-31 2009-05-07 Durect Corporation Composiciones deposito inyectables y empleo de las mismas.
DK1539101T3 (da) 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
ES2388623T3 (es) * 2002-09-05 2012-10-17 Catherine G. Ambrose Microesferas de antibiótico para el tratamiento de infecciones y osteomielitis
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
AU2003295409B2 (en) 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
EP1643968A1 (en) * 2003-05-30 2006-04-12 ALZA Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
TWI377958B (en) 2003-06-26 2012-12-01 Control Delivery Sys Inc In-situ gelling drug delivery system
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
EP1558215A4 (en) * 2003-10-14 2007-09-12 Wockhardt Ltd STERILE GELIFYING AGENTS
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2288371A1 (fr) * 2008-04-14 2011-03-02 Adocia Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un support organique
WO2009127940A1 (fr) * 2008-04-14 2009-10-22 Adocia Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
PL386099A1 (pl) * 2008-09-16 2010-03-29 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wielokompartmentowego implantu lipidowego
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
EA018472B1 (ru) * 2010-09-15 2013-08-30 Открытое Акционерное Общество "Протек" Частицы, содержащие эритропоэтин, для лечения и профилактики неврологических и гематологических заболеваний и нарушений
MX347014B (es) * 2010-11-24 2017-04-07 Durect Corp Composición para administración de fármaco biodegradable.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
JP6247400B2 (ja) * 2013-12-31 2017-12-13 ペベエベ・エスア 身体再建及び身体成形における使用のための制御放出脂肪酸組成物
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112017026746B1 (pt) * 2015-06-18 2023-11-28 Acuitybio Corporation Composições de liberação de fármacos implantáveis e uso de uma mistura compreendendo copolímero de plga, peg 8000 e paclitaxel
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
JPS57165392A (en) * 1981-04-06 1982-10-12 Toyo Jozo Co Ltd Long-acting cephalexin tablet
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US4650665A (en) * 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
JP2514201B2 (ja) * 1987-04-16 1996-07-10 横浜油脂工業株式会社 微粉状ｌ−アスコルビン酸被覆物の製造方法
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
JP2731862B2 (ja) * 1989-05-08 1998-03-25 富山化学工業株式会社 持続性製剤用組成物およびその製造法
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
US5085856A (en) * 1990-07-25 1992-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic water-in-oil emulsion lipstick comprising a phospholipid and glycerol fatty acid esters emulsifying system
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
GB9018839D0 (en) * 1990-08-29 1990-10-10 Newton John M Slow release compositions
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
DE69230032T2 (de) * 1991-12-19 2000-02-03 Mitsui Chemicals, Inc. Polyhydroxycarbonsäure und verfahren zu ihrer herstellung
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
TW282403B (hu) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6207199B1 (en) * 1994-01-27 2001-03-27 The Board Of Regents Of The University Of Oklahoma Process for making a particulate support matrix for making a rapidly dissolving dosage form
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
ES2171186T3 (es) * 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
JPH11505505A (ja) * 1994-06-27 1999-05-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ターゲッティングされた遺伝子輸送システム
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
ES2158611T3 (es) * 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CA2285591A1 (en) * 1997-04-03 1998-10-08 Point Biomedical Corporation Intravesical drug delivery system
US6365196B1 (en) * 1997-10-03 2002-04-02 Smithkline Beecham Corporation Controlled release solid dosage forms of lithium carbonate
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011850B2 (en) 1999-12-16 2006-03-14 Alza Corporation Dosage forms having a barrier layer to laser ablation

Also Published As

Publication number Publication date
US20060233841A1 (en) 2006-10-19
KR20020011995A (ko) 2002-02-09
AU5462900A (en) 2000-12-28
JP2003501375A (ja) 2003-01-14
AU779277B2 (en) 2005-01-13
NZ530701A (en) 2005-09-30
CA2372994C (en) 2010-03-23
ZA200109970B (en) 2002-12-04
WO2000074650A2 (en) 2000-12-14
NO20015888D0 (no) 2001-12-03
NZ515911A (en) 2004-02-27
CN100370967C (zh) 2008-02-27
CZ20014338A3 (cs) 2002-03-13
EP1183010A2 (en) 2002-03-06
HUP0201626A3 (en) 2004-05-28
WO2000074650A3 (en) 2001-07-05
CN1460018A (zh) 2003-12-03
IL146814A0 (en) 2002-07-25
MXPA01012471A (es) 2002-07-30
HK1060856A1 (en) 2004-08-27
PL351948A1 (en) 2003-07-14
RU2271196C2 (ru) 2006-03-10
NO20015888L (no) 2002-01-31
CA2372994A1 (en) 2000-12-14
KR100844295B1 (ko) 2008-07-07

Similar Documents

Publication Publication Date Title
HUP0201626A2 (hu) Beültethető gélkészítmények és eljárás gyártásukra
AU7729998A (en) Active principles and gas containing microparticles
WO2001074176A3 (en) Gelled and gellable compositions for food products
AU1111695A (en) Composition for the production of therapeutic products in vivo
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
HUP9903334A2 (hu) Eljárás morfológiailag egységes mikrokapszulák előállítására, valamint az ezzel az eljárással előállított mikrokapszulák
UA42734C2 (uk) Водорозчинна сіль німеcуліду, водний розчин солі німеcуліду, композиції на основі німеcуліду, спосіб отримання водорозчинної солі німеcуліду та фармацевтична композиція для лікування запалювальних захворювань
IL136085A0 (en) Prolamin-plant polar lipid combination, preparation method and applications
NO971965L (no) Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav
IS1983B (is) Ný þíeno[2,3-d]pýrimidíndíón, blöndur sem innihalda þau, aðferðir til framleiðslu þeirra og notkun þeirra í lækningalyf
DE59909854D1 (de) Partikulärer wirkstoffträger für die pulmonale applikation
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
AU1381697A (en) Method for preparation of active substances from nacre, resulting products, useful in medicinal applications
NZ336125A (en) Process for hydrating a gelling agent
AU2818595A (en) Process and apparatus for making rapidly dissolving dosage units and product therefrom
HU9503956D0 (en) High concentrated, solid mepiquat chloride and clormequat chloride products
BG105275A (en) Tan-1057 derivatives
PT1213974E (pt) Substancia bruta directamente compressivel para produtos comprimidos
HUP0102244A2 (hu) Fluid energiával végzett őrlési eljárás és az ehhez alkalmazott berendezés
PL355106A1 (en) Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
HUP0101822A2 (hu) Pezsegő kompozíciók és eljárás az előállításukra
HU9603489D0 (en) Medical composition and process for producing it
IL125474A0 (en) Solid instant-release forms of administration and process for producing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees